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 Abstract 
Alzheimer's disease (AD) is the leading cause of dementia, accounts for 60 to 80 percent cases. Two main factors called β-amyloid (Aβ) plaques and tangles 
are prime suspects in damaging and killing nerve cells. However, oxidative stress, the process which produces free radicals in cells, is believed to promote its 
progression to the extent that it may responsible for the cognitive and functional decline observed in AD. As of today there are few FDA approved drugs in 
the market for treatment, but their cholinergic adverse effect, potentially distressing toxicity and limited targets in AD pathology limits their use. Therefore, it 
is crucial to find an effective compounds to combat AD. We choose 45 plant-derived natural compounds that have antioxidant properties to slow down 
disease progression by quenching free redicals or promoting endogenous antioxidant capacity. However, we performed molecular docking studies to 
investigate the binding interactions between natural compounds and 13 various anti-Alzheimer drug targets. Three known Cholinesterase inhibitors 
(Donepezil, Galantamine and Rivastigmine) were taken as reference drugs over natural compounds for comparison and drug-likeness studies. Few of these 
compounds showed good inhibitory activity besides anti-oxidant activity. Most of these compounds followed pharmacokinetics properties that make them 
potentially promising drug candidates for the treatment of Alzheimer’s disease.  
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Graphical Abstract : Pharmacokinatics and Molecular docking studies of 45 natural antioxidant 
compounds with most known Alzheimer asscociated targets. 
 
 
 
 
 
Introduction 
Alzheimer’s disease  is one of the most common neurodegenerative disorders that normally cause dementia and affect the middle to old-aged 
persons, around one in four individuals over the age of 85[1]. Alzheimer's is a progressive disease, where dementia steadily gets worse over the 
years. The World Alzheimer Report 2015 led by King's College London found that there are currently around 46.8 million people living with 
dementia around the world, with numbers projected to nearly double every 20 years, increasing to 74.7 million by 2030 and 131.5 million by 
2050 (Fig. 1). At the country level, ten countries are home to over a million people with dementia in 2015: China (9.5 million), US (4.2 million), 
India (4.1 million), Japan (3.1 million), Brazil (1.6 million), Germany (1.6 million), Russia (1.3 million), Italy (1.2 million), Indonesia (1.2 
million) and France (1.2 million). Thus, this condition will bring gigantic financial and personal burdens to current and future generations. In 
order to deal with this problem, effective therapeutic and preventive interventions should be developed urgently. 
Figure 1 People living with dementia around the World: 9.4 million people of Americas, 4.0 million of African region,             of  Europian 
countries and             people of Asia are living with dementia in 2015. This no. will reach      and             in Americas,    and 
     million in Africa,      and    6         in Europe and      and             in Asia in 2030 and 2050 respectively. (World 
Alzheimer Report ) 
 
There are no such drugs/treatments available that can cure AD or any other common type of dementia completely. However, medications have 
been developed for Alzheimer's disease that can temporarily attenuate the symptoms, or delay it progression. The U.S. Food and Drug 
Administration (FDA) have approved two medications-cholinesterase inhibitors and Memantine. Over the past decade, much of the research on 
Alzheimer disease (AD) has focused on oxidative stress mechanisms and its importance in disease pathogenesis. The net effect of oxygen 
radicals is damaging, such damage present in AD includes advanced glycation end products [2], nitration [3], lipid peroxidation adduction 
products [4-5] as well as carbonyl-modified neurofilament protein and free carbonyls [6-7]. Significantly, this damage involves all neurons at 
risk to death in AD, not just those containing neurofibrillary tangles. 
Nature has gifted us lots of natural remedies in the form of  fruits, leaves, bark, vegetables and nuts, etc. The various ranges of  bioactive 
nutrients present in these natural products play a vital role in prevention and cure of various neurodegenerative diseases, such as AD, 
Parkinson’s disease and other neuronal dysfunctions. Previous studies  suggested that the  naturally occurring  phytochemicals, such as 
polyphenolic antioxidants found in fruits, vegetables, herbs and nuts, may potentially hinder neurodegeneration, and improve memory and 
cognitive functions. 
In our study, we chose 45 natural compounds (antioxident properties) of various plants from different databases (Table 1) for molecular docking 
and pharmacokinetics studies. Recent studies have demonstrated that the natural compounds and their derivatives possess wide range of  
biological activities like anti- tubercular, antifungal, antibacterial anti-malarial, anti-inflammatory and antioxidant activities [8-10].  
Table 1: List of studied compounds and soarces 
S. 
no. 
 
Compound Molecular 
Formula 
Plants and food sources 
1. 
 
Vitamin C C6H8O6 Kakadu plum, Camu Camu, Acerola, citrus fruits (such as oranges, sweet lime, etc.), green peppers, broccoli, green 
leafy vegetables, black currants, strawberries, blueberries, seabuckthorn, raw cabbage and tomatoes. 
2. Vitamin E C29H50O2 Wheat germ, seabuckthorn, nuts, seeds, whole grains, green leafy vegetables, kiwifruit, vegetable oil and fish-liver oil 
3. Coenzyme Q10 C59H90O4 Sardine, Mackrel ,beef, pork, chicken heart, chicken liver, rapeseed oil, soybean oil, sesame oil, peanuts, parsley, 
perilla, broccoli, grapes, cauliflower,  avocados etc 
4. Iodide I− Sea vegetables, cranberries, yogurt, navy beans, strawberries, raw cheese, potatoes etc. 
5. Melatonin C13H16N2O2 Cherries, bananas, grapes, rice, cereals, herbs, plums, olive oil, wine, beer, pineapple, oranges etc. 
6. Alpha carotene C40H56 Carrots, sweet potatoes, pumpkin, winter squash, broccoli, green beans, green peas, spinach, turnip greens, collards, 
leaf lettuce, avocado, parsley etc.  
7. Astaxanthin C40H52O4 Microalgae, yeast, Salmon, Trout, Krill, Shrimp, Crayfish, crustaceans etc. 
8. Beta carotene C40H56 Butternut squash, carrots, orange bell peppers, pumpkins, kale, peaches, apricots, mango, turnip greens, broccoli, 
spinach, and sweet potatoes. 
9. Canthaxanthin C40H52O2 Pacific salmon, green algae, crustacean and fishes like Crap, Golden mullet, Seabream and Trush wasse. 
10. Lutein C40H56O2 Spinach, kale, Swiss chard, collard greens, beet and mustard greens, endive, red pepper and okra. 
11. Lycopene C40H56 Cooked red tomato products like canned tomatoes, tomato sauce, tomato juice and garden cocktails, guava, red 
carrots, watermelons, gac, papayas etc. 
12. Zeaxanthin C40H56O2 Paprika, corn, saffron, wolfberries, Spirulina, dark green leafy vegetables, such as kale, spinach, turnip greens, 
collard greens, romaine lettuce, watercress, Swiss chard and mustard greens. 
13. Apigenin C15H10O5 Parsley, celery, celeriac, chamomile tea, flowers of chamomile plants,  Navy bean etc 
14. Luteolin C15H10O6 Salvia tomentosa, celery, broccoli, green pepper, parsley, thyme, dandelion, perilla, chamomile tea, carrots, olive oil, 
peppermint, rosemary, navel oranges, oregano, seeds of the palm Aiphanes aculeate etc. 
15. Tangeritin C20H20O7 Tangerine and other citrus peels. 
16. Isorhamnetin C16H12O7 Pungent yellow or red onions, Mexican terragon (Tagetes lucida) etc. 
17. Kaempferol C15H10O6 Apples, grapes, tomatoes, green tea, potatoes, onions, broccoli, Brussels sprouts, squash, cucumbers, lettuce, green 
beans, peaches, blackberries, raspberries, and spinach. Plants that are known to contain kaempferol include Aloe vera, 
Coccinia grandis, Cuscuta chinensis, Euphorbia pekinensis, Glycine max, Hypericum perforatum, Moringa oleifera, 
Rosmarinus officinalis, Sambucus nigra, and Toona sinensis.  
18. Myricetin C15H10O8 Vegetables, fruits, nuts, berries, tea, and is also found in red wine. 
19. Quercetin C15H10O7 Capers, lovage, dock like sorrel, radish leaves, carob fiber, dill, cilantro, Hungarian wax peppers, funnel leaves, onion 
(red), radicchio, watercress, buckwheat, kale etc. 
20. Eriodictyol C15H12O6 In twigs of Millettia duchesnei, in Eupatorium arnottianum, and its glycosides (eriocitrin) in lemons and rose hips 
(Rosa canina). 
21. Hesperetin C16H14O6 Lemons and sweet oranges. 
22. Naringenin C15H12O5 Grapefruit, oranges, tomatoes (skin) and in water mint. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23. Catechin C15H14O6 Uncaria rhynchophylla, pome fruits, cocoa, prune juice, broad bean pod, acai oil, argan oil, peaches, green tea, 
vinegar, barley grain, etc 
24. Gallocatechin C15H14O7 Green tea, bananas, persimmons and pomegranates. 
25. Epicatechin  Uncaria rhynchophylla, cacao beans, green tea etc. 
26. Epigallocatechin  St John's wort etc. 
27. Theaflavin C29H24O12 Black tea etc. 
28. Daidzein C15H10O4 Kwao Krua (Pueraria mirifica), Kudzu (Pueraria lobata), Maackia amurensis cell cultures, soybeans, lupin, fava 
beans, psoralea, Flemingia vestita, F. marophylla and coffee. 
29. Ganistein C15H10O5 Lupin, fava beans, soybeans, kudzu, Flemingia vestita, F. macrophylla, coffee, Maackia amurensis cell cultures etc. 
30. Glycitein C16H12O5 Soy food products. 
31. Resveratrol C14H12O3 Skin of grapes, blueberries, raspberries, mulberries, lingonberry, senna and concentrated in red wine. 
32. Pterostilbene C16H16O3 Almonds, various Vaccinium berries, grape leaves,  vines and blueberries.  
33. Cyanidin C15H11O6
+
 Grapes, bilberry, blackberry, blueberry, cherry, cranberry, elderberry, hawthorn, loganberry, açai berry, raspberry,  
apples, plums, red cabbage and red onion. 
34. Delphinidin C15H11O7
+
 Cranberries, Concord grapes, pomegranates, bilberries etc 
35. Malvidin C17H15O7+ Primula plants, blue pimpernel (Anagallis monelli), red wine, Vitis vinifera, chokeberries (Aronia sp), saskatoon 
berries (Amelanchier alnifolia) etc. 
36. Pelargonidin C15H11O5
+
 Red geraniums (Geraniaceae),  Philodendron (Araceae), flowers of blue pimpernel (Anagallis monelli, Myrsinaceae), 
raspberries, strawberries, blueberries, blackberries, cranberries, saskatoon berries, chokeberries, plums  
pomegranates, kidney beans etc. 
37. Peonidin C16H13O6
+
 Raw cranberries, blueberries, plums, grapes, cherries, purple fleshed sweet potatoes, raw black rice and black 
bananas. 
38. Petunidin C16H13O7
+
 
(Cl
−
) 
Chokeberries (Aronia sp), Saskatoon berries (Amelanchier alnifolia) or different species of grape (for instance Vitis 
vinifera, or muscadine, Vitis rotundifolia), Indigo Rose tomatoes. 
39. Cichoric acid C22H18O12 Cichorium intybus (chicory), E. purpurea, dandelion leaves, basil, lemon balm, and aquatic plants, including algae 
and seagrasses. 
40. Chlorogenic 
acid 
C16H18O9 Leaves of Hibiscus sabdariffa, potatoes, flesh of eggplants,peach, prunes, green coffee bean extract and green tea. 
41. Cinnamic acid C9H8O2 Oil of cinnamon, balsams such as storax, shea butter, seeds of plants such as brown rice, whole wheat, oats, coffee, 
apple, artichoke, peanut, orange and pineapple. 
42. Ellagic acid C14H6O8 North American white oak (Quercus alba, European red oak (Quercus robur). Myriophyllum spicatum, medicinal 
mushroom Phellinus linteus, walnuts, pecans, cranberries, raspberries, strawberries, and grapes, as well as distilled 
beverages, peach and other plant foods. 
43. Gallic acid C7H6O5 Parasitic plant Cynomorium coccineum, the aquatic plant Myriophyllum spicatum, the blue-green alga Microcystis 
aeruginosa. oak species, Caesalpinia mimosoides, and in the stem bark of Boswellia dalzielii, fruits (including 
strawberries, grapes, bananas), as well as teas, cloves and vinegars. 
44. Rosmarinic acid C18H16O8 Ocimum basilicum (basil), Ocimum tenuiflorum (holy basil), Melissa officinalis (lemon balm), Rosmarinus officinalis 
(rosemary), Origanum majorana (marjoram), Salvia officinalis (sage), thyme and peppermint, (Prunella vulgaris) 
Heliotropium foertherianum Maranta (Maranta leuconeura, Maranta depressa) and Thalia (Thalia geniculata). 
45. Salicyclic acid C7H6O3 Blackberries, blueberries, cantaloupes, dates, grapes, kiwi fruits, guavas, apricots, green pepper, olives, tomatoes, 
radish, chicory and mushrooms. Some herbs and spices contain high amounts, Of the legumes, seeds, nuts and 
cereals, only almonds, water chestnuts and peanuts have significant amounts.  
In our study, all the 45 compounds  have antioxidant properties and it has been shown that treatment with these compounds certainly contribute 
to their neuroprotective effects and it is  a potential approach for slowing disease progression. Therefore, we further screened our compounds 
against Alzheimer, which is caused by oxidative stress and it is one of the main factors in progression of Alzheimer [11-12]. Natural compounds 
that have antioxidant properties exhibit their antioxidant effect by quenching free redicals or promoting endogenous antioxidant capacity and 
some of these stimulate the synthesis of endogenous antioxidant molecules in cell via activation of Nrf/ARE pathways. Therefore, these 
compounds can be good candidates for the assessment of the AD by scavenging free radicals. Oxidative stress and its sources in AD are 
illustrated in (Fig. 2). 
Figure 2 Antioxidant strategies and sources of oxidative stress in AD. 
 
In our study we also took three cholinesterase inhibitors (Donepezil, Galantamine and Rivastigmine), which are commonly prescribed drugs in 
Alzheimer, as reference compounds over our natural compounds for drug-likeness studies. Mechanism of action of these drugs by  preventing an 
enzyme called acetylcholinesterase, which  breaks down acetylcholine in the brain and enhances antioxidants effects and attenuates  oxidative 
stresses[13-14]. As a result of our investigation, we found that our natural compounds showed promising inhibitory activity also. Some of them 
were found to have even better activity than prescribed drugs against AD targets. Any compound cannot be directly considered as a drug 
molecule unless it is validated by several  parameters like pharmacokinetic properties, ADME  properties, and potential toxicity. Therefore, with 
the help of various bioinformatics tool, we validated all our compounds. 
Molecular docking studies are used to find out the interaction between a ligand/drug and a protein at the atomic level which allows us to 
characterize the behaviour of our compounds in the binding site of  targets as well as to explain fundamental biochemical processes [15]. Each of 
the natural compounds were docked with all 13 AD associated proteins individually, to determine the best binding affinity using 
Autodock4.2[16]. Further, these compounds could be useful for the identification and development of new preventive and therapeutic drug 
against Alzheimer disease . 
 
 
 
Materials and Method 
Natural Compounds Selection 
Fourty-five  natural compounds were selected  as common  reported  antioxidant  natural compounds from various database and literature . All 
chemical structures of these compunds were sketched in ChemBioDraw Ultra 12.0 (CambrigdeSoft) as shown in (Fig. 3). 
Figure 3: Chemical structures of the studied compounds. 
 
 
Basic Pharmacokinetics Parameters Calculation 
A compound has to be passed through multiple filters to be considered a novel drug. Most of the compounds that fail in pre-clinical trials do so 
because they do not show the required pharmacological properties to be a drug molecule [17]. Pharmacokinetics properties such as absorption, 
distribution, metabolism, excretion, and toxicity (ADMET) has play a very crucial role in development of drug design to the final clinical 
success of a drug candidate [18]. Therefore, prediction of ADMET properties was done earlier with the aim of decreasing the failure rate of the 
compound for further process in future. Pharmacokinetics properties of natural compounds such as  MW (molecular weight), LogP, 
HBD(number of hydrogen bond donors), HBA (number of hydrogen bond acceptors) , TPSA (topological polar surface area), nrtB (number of 
rotatable bonds) , nViolation (violations of Lipinski’s rule of five) [19] were calculated by DruLito (Drug LiknessTool) 
(www.niper.gov.in/pi_dev_tools/DruLiToWeb/DruLiTo_index.html). and Molinspiration Online tool  (http://www.molinspiration.com/). 
Compound Toxicity Prediction 
The compounds toxicities prediction is an important sect of the drug design development process. In silico toxicity assessments are not only 
faster, but can also reduce the amount of animal experiments. So, calculated LD50 values of all our natural compounds. LD50 value is the amount 
of doses given to kill 50% of a test population (lab rats or other animals).  It is an index determination of medicine and poison’s virulence. The 
lower the LD50 dose, the greater is the toxicity of the substance. These LD50 values were calculated by an online tool ProTox[20]. We also 
determined its carcinogenic, mutagenic and skin irritation properties by using Discovery Studio 2.5 (Accelrys Software Inc., San Diego, CA, 
USA). 
 
 
Molecular Docking 
Target preparation 
All the 13 Alzheimer disease associated targets were downloaded from Protein Data Bank (PDB) (http://www.rcsb.org/pdb/home/home.do) and 
are listed in (Table 2). For crystal structure of each target, the crystallographic water molecules were removed, the missing hydrogen atoms were 
added and the energy level of all the 13 targets was minimised using swiss_PDB viewer tool [21]. 
Table 2: 13 Alzheimer disease associated targets 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ligand preparation 
The structure of all the 45 compounds were drawn in ChemDraw12 (PerkinElmer Informatics, Waltham, MA, USA) and converted to their 3D 
form and also geometry of the compounds was optimized in ChemBio3DUltra12 (PerkinElmer Informatics, Waltham, MA, USA). Finally all 
compounds were saved in PDB format for further docking studies. 
 
 
S.No PDB ID Protein Name References 
1 1EQG Cyclooxygenase-1 (COX-1) [26] 
2 1MX1 Human carboxylesterase (hCE-1) [27] 
3 1PBQ N-methyl-D-aspartate (NMDA) [28] 
4 1Q5K Glycogen-synthase-kinase-3β (GSK-3β) [29] 
5 1QWC Nitric oxide synthase (NOS) [30] 
6 1UDT Phosphodiesterase-5 (PD-5) [31] 
7 2FV5 TNF-α converting enzyme (TACE) [32] 
8 3BKL Angiotensin converting enzyme (ACE) [33] 
9 3G9N c-Jun N-terminal kinase (JNK) [34] 
10 3QMO Cyclooxygenase-2 (COX-2) [35] 
11 4B0P Butyrylcholinesterase (BuChE) [36] 
12 4DJU β-Site amyloid precursor protein [37] 
13 4EY5 Acetylcholinesterase (AChE) [38] 
Target Lignad docking 
Docking studies yielded crucial information concerning the orientation of the inhibitors in the binding pocket of the target proteins. During the 
molecular docking process, all the natural compounds bound in the groove of their respective targets. Each of the compounds was docked with 
all the 13 AD associated targets, hence total 585 dockings were performed (Table 3). Then we used 3D sorting method to filter out the best 
possible compounds from the pool of 45 natural compounds.  
 
Table 3: Binding energies of  all the 45 natural compounds and 03 reference drugs docked with 13Alzheimer disease associated targets. 
 
 1EQG 1MX1 1PBQ 1Q5K 1QWC 1UDT 2FV5 3BKL 3G9N 3QMO 4B0P 4DJU 4EY5 
Affinity 
(kcal.mol) 
Affinity 
(kcal/mol) 
Affinity 
(kcal.mol) 
Affinity 
(kcal/mol) 
Affinity 
(kcal/mol) 
Affinity 
(kcal/mol) 
Affinity 
(kcal/mol) 
Affinity 
(kcal/mol) 
Affinity 
(kcal/mol) 
Affinity 
(kcal/mol) 
Affinity 
(kcal/mol) 
Affinity 
(kcal/mol) 
Affinity 
(kcal/mol) 
Alpha carotene -7.6 -7.3 -7.2 -8.6 -7.3 -7.5 -6.8 -7.6 -7.5 -7.4 -8 -8.8 -7.1 
Apigenin -9.1 -9.3 -8.4 -8.7 -9.3 -9.4 -8.0 -8.3 -7.8 -7.4 -7.9 -8.4 -8.9 
Astaxanthin -8.2 -7.9 -7.4 -8.7 -6.2 -7.0 -8.0 -10.0 -8.1 -7.4 -8.7 -9.4 -9.2 
Beta carotene -7.9 -7.1 -8.7 -7.4 -9.0 -7.7 -7.6 -7.8 -7.3 -7.9 -8.5 -9.3 -7.1 
Canthaxanthin -8.4 -7.9 -7.8 -8.1 -9.2 -7.2 -8.2 -7.6 -8.7 -7.5 -7.9 -7.4 -6.9 
Catechin -8.7 -9.4 -8.5 -9.7 -9.9 -7.7 -10.1 -10.4 -9.0 -7.6 -10.6 -9.5 -9.6 
Chicoric acid -8 -6.6 -7.3 -8.5 -8.6 -7.1 -8.5 -8.6 -7.4 -7.2 -9.6 -7.3 -8.2 
chlorogenic acid -7.6 -7.4 -6.9 -8.5 -4.8 -6.5 -9.8 -7.8 -7.5 -7.5 -8.3 -7.4 -7.6 
Cinnamic acid -5 -5.5 -4.2 -6.2 -4.7 -6.5 -4.7 -6.1 -4.7 -6.3 -5.4 -5.7 -4.8 
Coenzyme Q10 -6.1 -4.8 -4.8 -7.5 -5.1 -6.7 -7.9 -6.8 -6.8 -5.6 -8.2 -7.1 -5.5 
Cyanidin -9.4 -7.2 -8.5 -8.4 -7.9 -7.7 -9.6 -8.9 -7.9 -7.6 -9.2 -8.2 -8.8 
Daidzein -8.5 -7.3 -7.8 -8.4 -7 -8.6 -9.3 -8.2 -7.7 -8.3 -8.3 -8.7 -8.2 
Delphinidin -8.1 -7.9 -7.6 -9.0 -8.6 -7.2 -9.6 -8.3 -8.4 -9.2 -9.3 -8.3 -8.6 
Ellagic acid -7.3 -7.5 -8.2 -9.4 -8.4 -9.7 -8.3 -8.3 -7.6 -8.1 -10.5 -8.1 -9.7 
Epicatechin -9 -7.4 -7.9 -8.7 -9.7 -9.5 -9.5 -8.3 -7.5 -8.9 -8.9 -8.2 -8.2 
Epigallocatechin -7.9 -7.5 -7.5 -8.1 -6.9 -9.6 -8.3 -8.3 -7.5 -9 -8.8 -7.7 -7.9 
Eriodictyol -9.5 -7.6 -7.8 -8.7 -7 -9.5 -9.8 -8.4 -7.6 -9.4 -9.4 -8.2 -8.3 
Gallic acid -6.2 -5.6 -5.8 -6 -6.2 -6.1 -6.9 -6.3 -5.8 -5.2 -6.4 -5.5 -6.4 
Gallocatechin -7.9 -7.5 -7.4 -8.2 -6.9 -9.6 -7.4 -8.2 -7.4 -7.6 -9.2 -7.8 -8.4 
Genistein -7.7 -7.4 -8.7 -8.8 -9.6 -7.2 -9 -8.3 -8 -7.8 -7.9 -9.1 -8.6 
Glycitein -7.4 -8.1 -7.5 -9.1 -6.8 -7.8 -7.9 -9.4 -7.2 -7.3 -8.1 -10.2 -9.1 
Hesperetin -8.2 -7.6 -8.3 -8.4 -7.1 -7.2 -9.2 -8.4 -7.9 -9.2 -9.1 -8.4 -8.4 
Iodide -4 -3.9 -4.6 -4.3 -4.7 -3.5 -5.1 -4.4 -4.3 -3.8 -4.5 -4.1 -3.5 
Isorhamnetin -9.5 -7 -7.6 -8.8 -7.3 -8.5 -8.9 -7.8 -8 -9 -9.2 -8.4 -7.3 
Kaempferol -7.7 -7.2 -7.4 -8.8 -6.8 -8.7 -9.0 -8.2 -8.2 -8.9 -7.8 -8.5 -8.9 
Lutein -8.6 -8.4 -6.5 -7.5 -7.8 -7.7 -9.3 -7.6 -8 -7.1 -8.6 -8.9 -7.3 
Luteolin -8 -7.6 -8.6 -8.7 -9.0 -9.8 -9.7 -8.5 -7.8 -9.2 -9.7 -8.4 -8.6 
Lycopene -6.4 -6.6 -6.6 -6.2 -1.9 -7.4 -8.0 -7.8 -6.8 -6.2 -6.8 -7.1 -6.2 
Malvidin -8.5 -6.8 -7.3 -8.5 -8.2 -7.5 -8.7 -8 -7.5 -8.8 -8.9 -8.1 -7.9 
Melatonin -7.5 -6.5 -6.9 -7.1 -5.5 -7.9 -6.1 -7.2 -6.4 -6.8 -7.9 -7 -7.2 
Myricetin -9.2 -7.1 -7.6 -8.9 -7.1 -6.5 -8 -8.3 -8 -8 -9.4 -7.9 -8.5 
Naringenin -8.5 -7.3 -7.5 -8.6 -9.5 -9.5 -9 -8.3 -7.6 -9 -9.1 -8.2 -8.5 
Pelargonidin -8.3 -8.1 -9.1 -9.7 -10.1 -6.9 -8 -9.4 -9 -7.9 -10.1 -9 -10.3 
Peonidin -7.1 -7.3 -7.6 -8.4 -9.2 -9 -9.4 -8.1 -7.6 -9.2 -9 -8.1 -8.9 
Petunidin -8 -7.1 -7.6 -9.0 -8.6 -9.4 -8.8 -8.2 -8.4 -7.6 -9.3 -8.2 -8 
Pterostilbene -7.2 -6.4 -7 -7.5 -6.5 -8.4 -7.8 -7.5 -6.2 -7.7 -7 -7.6 -7.5 
Quercetin -9.5 -7.1 -7.6 -8.5 -7.3 -9.4 -9.2 -8.5 -8.7 -8.4 -9.4 -8.2 -8.5 
Resveratrol -6.5 -6.5 -6.9 -7.3 -8.5 -6.4 -8.6 -7.2 -6.4 -6.5 -7.6 -7.4 -8 
Rosmarinic acid -7.9 -7.4 -5.8 -8.5 -7.8 -7.1 -8.3 -8.5 -5.9 -8.1 -9.2 -7.4 -8.2 
Salicyclic acid -5.5 -5.8 -5.7 -5.9 -4.9 -5.4 -6.2 -6.2 -5.2 -5.4 -5.7 -5.1 -6.3 
Tangeritin -6.8 -6.8 -7.8 -8 -6.8 -9 -8.2 -7.8 -7.6 -7.4 -7.1 -8.2 -8 
Theaflavin -9.8 -8.6 -10.8 -11.4 -8.9 -8 -11.2 -11.3 -8.9 -9.3 -10.2 -10.8 -11.1 
Vitamin C -5.1 -5.1 -5.3 -5.4 -5.8 -4.8 -6.7 -6.1 -5.1 -5.6 -5.8 -5.5 -5.3 
Vitamin E -6.8 -5.7 -7.3 -5.4 -4.7 -5.2 -4.1 -5 -5 -5.2 -5.9 -3.7 -5 
Zeaxanthin -7.8 -7.8 -7.5 -8 -8.2 -6.9 -7.8 -8.7 -8.3 -7.2 -8.4 -9.6 -7.9 
Drugs commonly prescribed in Alzheimer disease 
Donepezil -8.9 -6.5 -7.5 -8.9 -9.8 -6.7 -6.4 -8.1 -8.6 -7.6 -7.7 -8.6 -7.5 
Galantamine -7.4 -6.5 -5.7 -6.8 -8.0 -5.8 -6.4 -7.7 -6.7 -6.8 -6.8 -6.3 -6.5 
Rivastigmine -6.4 -6.1 -6.6 -6.7 -8.3 -5.2 -7.2 -6.1 -6.1 -5.9 -7.2 -6.2 -6.2 
 
 
 This method can be defined as filtering out the best using 3 levels of selection, first on the basis of the score (docking), second in addition to  
ranks the compounds on the basis of  interaction with number of receptors and finally eliminating those that violate the minimum criterion for 
RO5 (Lipinski Rule of Five) and toxicity. The docking interactions were visualized with PYMOL molecular graphics system, version 1.7.4.4 
(Schrödinger, LLC, and Portland, OR, USA) and Maestro Visualizer (Maestro, Schrödinger, LLC, New York, NY, 2017.). The docking studies 
were performed using Autodock4.0[22]. The inhibition constant (Ki) of  natural compounds against Alzhiemer associated targets was calculated 
from docking energy using the following equation: 
                    
Where     = docking energy               cal K−1 mol−1             ,     = inhibition constant (nM) 
Results 
Pharmacokinetics Properties 
Pharmacokinetics properties of natural compounds to be considered as drug candidates were based on Lipinski’s rule of five This rule is 
formulated for most orally administered drugs, it uses four criteria to determine if a molecule is druglike; to have a molecular weight of     , a 
LogP (logarithm of partition coefficient)   , five or fewer hydrogen bond donor sites, and ten or fewer hydrogen bond acceptor sites. 
Molecules violating more than one of these rules may have problems with bioavailability. The entire set of compounds well followed the RO5 
(Rule of 5) except 15 of the compounds, out of which  eight compounds (Alpha carotene, Astaxanthin, Beta carotene, Canthaxanthin, Coenzyme 
Q10, Epigallocatechin, Gallocatechin and Theaflavin)  violating more than one of these rules  and seven compounds violationg only single rule 
(Chlorogenic acid, Delphinidin, Gallic acid, Lycopene, Myricetin, Vitamin C, Vitamin E ) that created the Lipinski’s rule violation by having  
                  ,         and                  that can create a problem in oral bioavailability. 
TPSA analysis checked the bioavailability of natural compounds, As per the Veber’s rule for good oral bioavailability, the number of rotatable bond must be 
   , and TPSA values       [23].  The number of rotatable bonds has been shown to be a very good descriptor of oral bioavailability of drugs and has 
been found better to discriminate between compounds that have oral bioavailability of drugs. Rotatable bond is defined as any single non-ring bond, bounded 
to non-terminal heavy (ie, non-hydrogen) atom. Amide C–N bonds are not considered because of their high rotational energy barrier [24]. The numbers of 
rotatable bonds in all of our compounds were found to be appropriate as in reference compounds (Donepezil, Galantamine and Rivastigmine) except four 
compounds (Vit E, Chicoric acid, CoenzymeQ10, Lycopene) have         . Once TPSA was calculated and it was found that only four compounds 
(Chicoric acid, Chlorogenic acid, Rosmarinic acid and Theaflavin ) have TPSA values ≤ 140Å, then we calculated percentage of absorption for all the 45 
compounds using Zhao et al. formula[25]. 
 
                                                     
 
According to above formula, we calculated percentages of absorption of our compounds and as well as our reference compounds. Compounds 
(Theaflavin, Chicoric acid, Chlorogenic acid, Myricetin and Rosmarinic acid  ) have poor absorbance percentage                   
       ,          and          respectively, further details are given in (Table 4). 
Table 4: Shows the drug likeness of compounds and violation of Lipinski's rule are highlighted in red colour. 
 
 
S. No. Ligand Molecular 
Formula 
Molecular 
Weight (g/mol) 
logP H-Bond 
Acceptors 
H-Bond 
Donors 
TPSA % ABS nRB nAtom nViolation 
1 Alpha carotene C40H56 536.44 15.187 0 0 0 109.00 10 96 2 
2 Apigenin C15H10O5 270.05 1.567 1 3 86.99 79.901 1 30 0 
3 Astaxanthin C40H52O4 596.39 9.696 4 2 74.6 84.046 10 96 2 
4 Beta carotene C40H56 536.44 14.734 0 0 0 109.00 10 96 2 
5 Catechin C15H14O6 290.08 0.406 1 5 110.38 72.077 1 35 0 
6 Canthaxanthin C40H52O2 564.4 10.788 2 0 34.14 97.580 10 94 2 
7 Chicoric acid C22H18O12 472.06 0.722 8 4 213.78 37.490 11 50 0 
8 Chlorogenic acid C16H18O9 353.09 -0.928 7 5 167.58 52.944 5 42 1 
9 Cinnamic acid C9H8O2 147.04 3.423 2 0 40.13 95.576 2 18 0 
10 Coenzyme Q10 C59H90O4 862.68 18.454 4 0 52.6 91.405 31 153 2 
11 Cyanidin C15H11O6
+
 287.06 0 1 5 101.15 75.165 1 32 0 
12 Daidzein C15H10O4 254.06 2.475 1 2 66.76 86.668 1 29 0 
13 Delphinidin C15H11O7
+
 303.05 0 1 6 121.38 68.398 1 33 1 
14 Ellagic acid C14H6O8 299.99 0.652 8 2 93.06 77.871 0 26 0 
15 Epicatechin C15H14O6 290.08 0.406 1 5 110.38 72.077 1 35 0 
16 Epigallocatechin C15H14O7 306.07 -0.128 1 6 130.61 65.310 1 36 2 
17 Eriodictyol C15H12O6 288.06 0.363 1 4 107.22 73.134 1 33 0 
18 Gallic acid C7H6O5 169.01 -0.479 2 3 100.82 75.275 1 17 0 
19 Gallocatechin C15H14O7 306.07 -0.128 1 6 130.61 65.310 1 36 1 
20 Genistein C15H10O5 270.05 1.043 5 3 86.99 79.901 1 30 0 
21 Glycitein C16H12O5 284.07 2.031 1 2 75.99 83.581 2 33 0 
22 Hesperetin C16H14O6 302.08 0.453 1 3 96.22 76.814 2 36 0 
23 Iodide I− 144.14 0.035 1 0 17.07 103.29 4 28 0 
24 Isorhamnetin C16H12O7 316.06 1.471 2 4 116.45 70.047 2 35 0 
25 Kaempferol C15H10O6 286.05 1.915 2 4 107.22 73.134 1 31 0 
26 Lutein C40H56O2 568.43 11.283 2 2 40.46 95.466 10 98 1 
27 Luteolin C15H10O6 286.05 1.033 1 4 107.22 73.134 1 31 0 
28 Lycopene C40H56 536.44 14.586 0 0 0 109.00 16 96 1 
29 Malvidin C17H15O7+ 331.08 0 1 4 99.38 75.757 3 39 0 
30 Melatonin C13H16N2O2 232.12 1.254 3 2 50.36 92.154 5 33 0 
31 Myricetin C15H10O8 318.04 0.847 2 6 147.68 59.601 1 33 1 
32 Naringenin C15H12O5 272.07 0.897 1 3 86.99 79.901 1 32 0 
33 Pelargonidin C15H11O5
+
 271.06 0 1 4 80.92 81.932 1 31 0 
34 Peonidin C16H13O6
+
 301.07 0 6 4 90.15 78.844 2 35 0 
35 Petunidin C16H13O7
+
 (Cl
−
) 317.07 0 1 5 110.38 72.077 2 36 0 
36 Pterostilbene C16H16O3 256.11 2.69 3 1 38.69 96.058 4 35 0 
37 Quercetin C15H10O7 302.04 1.381 2 5 127.45 66.367 1 32 0 
38 Resveratrol C14H12O3 228.08 3.436 0 3 60.69 88.699 2 29 0 
39 Rosmarinic acid C18H16O8 359.08 1.602 4 4 147.35 59.711 7 41 0 
40 Salicyclic acid C7H6O3 137.02 0.8 2 1 60.36 88.809 1 15 0 
41 Tangeritin C20H20O7 372.12 2.236 1 0 72.45 84.765 6 47 0 
42 Theaflavin C29H24O12 564.13 -0.216 4 9 217.6 36.212 2 65 2 
43 Vitamin C C6H8O6 175.02 -1.813 6 2 83.83 80.958 2 19 0 
44 Vitamin E C29H50O2 430.38 10.938 0 1 29.46 99.145 12 81 1 
45 Zeaxanthin C40H56O2 568.43 10.564 2 2 40.46 95.466 10 98 1 
Three Cholinesterase inhibitors are commonly prescribed in Alzheimer disease  
1 Donepezil C24H30NO3
+
 380.50 3.65 1 4 39.97 95.23 6 58 0 
2 Galantamine C17H12NO3
+
 288.36 1.54 2 4 43.13 94.14 1 43 0 
3 Rivastigmine C14H23N2O2
+
 251.34 2.28 1 4 33.98 97.27 6 41 0 
  
 
Toxicity Prediction 
The computational prediction of toxicities, drug score profiles of natural compounds are promising. An online software  PROTOX  was  used  for  the  
prediction of the LD50 of  the  new compounds. Most of the compounds in our study fell in non-toxic zone (above the          )  except Lutein       
   , Myricetin           , Quercetin           , Salicyclic acid             and Zeaxanthin          , results are shown in the graph in (Fig. 
4). The mutagenicity, carcinogenicity and skin irritation properties were also predicted and it wasfound that 05 compounds are mutagenic, 07 compounds are 
carcinogenic, 38 compounds are very sensitive to skin but 09 of these compounds may cause severe skin irritation problems. Results are listed in (Table 5).  
Figure 4 Histogram representation of      values of natural compounds compared with 
commonly prescribes drugs. 
 
Table 5: Shows the toxicity of compounds and various toxicitiness are highlighted in red colour. 
 
 
 
 
 
  
%ABS- Percentage of Absorption               TPSA- Topological Polar Surface Area           nrtB- Number of rotable Atoms 
nAtom- Number of Atoms                           nViolation- Violation of Lipinski’s rule          XlogP  ≤  5 
H-BD  < 5                                                     H-BA  < 10                                                       MW    < 500 
  
 
 
 
S. no. Compound Carcinogenicity Mutagenicity Skin 
Irritation 
Skin 
Sensitization 
Biodegradability 
1 Alpha carotene Carcinogen Non mutagen Severe Weak Degradable 
2 Apigenin Non carcinogen Non mutagen None Strong Non degradable 
3 Astaxanthin Non carcinogen Non mutagen Mild Weak Degradable 
4 Beta carotene Carcinogen Non mutagen Severe Weak Degradable 
5 Catechin Non carcinogen Non mutagen None Strong Non degradable 
6 Canthaxanthin Carcinogen Non mutagen Severe Weak Degradable 
7 Chicoric acid Non carcinogen Non mutagen None Strong Degradable 
8 Chlorogenic acid Non carcinogen Non mutagen Mild None Degradable 
9 Cinnamic acid Carcinogen Non mutagen Mild Strong Degradable 
10 Coenzyme Q10 Carcinogen Non mutagen Severe None Degradable 
11 Cyanidin Non carcinogen Non mutagen None Strong Non degradable 
12 Daidzein Non carcinogen Non mutagen None Strong Non degradable 
13 Delphinidin Non carcinogen Non mutagen None Strong Non degradable 
14 Ellagic acid Non carcinogen Non mutagen Mild Weak Non degradable 
15 Epicatechin Non carcinogen Non mutagen None Strong Non degradable 
16 Epigallocatechin Non carcinogen Non mutagen None Strong Non degradable 
17 Eriodictyol Non carcinogen Non mutagen None Strong Non degradable 
18 Gallic acid Non carcinogen Non mutagen None Strong Degradable 
19 Gallocatechin Non carcinogen Non mutagen None Strong Non degradable 
20 Genistein Non carcinogen Non mutagen None Strong Non degradable 
21 Glycitein Non carcinogen Non mutagen None None Degradable 
22 Hesperetin Non carcinogen Non mutagen None Strong Degradable 
  
 
 
 
Molecular docking Studies 
To ensure the interaction between the natural compounds and Alzheimer disease associated targets, we performed molecular docking analysis using 
Autodock4.2. Each of the compounds was docked with all the 13 Alzheimer disease associated targets individually.  These compounds showed very good 
binding affinity with all the 13 Alzheimer associated targets.  
Among all of the compounds only 09 compounds interacted with maximum number of targets, such as            showed maximum interactions, as it 
interacted with    Alzheimer associated targets (    ,     ,     ,     ,     ,     ,     ,     ,     ,      and     );  whereas compound 
         interacted with    targets (    ,     ,                       ,     ,                    ),              interacted with 
    targets (                      and     ),          intercalated with     targets (                       and     ), 
23 Iodide Non carcinogen Non mutagen Severe Weak Degradable 
24 Isorhamnetin Non carcinogen Mutagen None Strong Non degradable 
25 Kaempferol Non carcinogen Mutagen None Strong Non degradable 
26 Lutein Non carcinogen Non mutagen Severe Weak Degradable 
27 Luteolin Non carcinogen Non mutagen None Strong Non degradable 
28 Lycopene Carcinogen Non mutagen Severe Weak Degradable 
29 Malvidin Non carcinogen Non mutagen None Strong Non degradable 
30 Melatonin Non carcinogen Non mutagen None None Non degradable 
31 Myricetin Non carcinogen Mutagen None Strong Non degradable 
32 Naringenin Non carcinogen Non mutagen None Strong Non degradable 
33 Pelargonidin Non carcinogen Non mutagen None Strong Non degradable 
34 Peonidin Non carcinogen Non mutagen None Strong Non degradable 
35 Petunidin Non carcinogen Non mutagen None Strong Non degradable 
36 Pterostilbene Non carcinogen Mutagen None Strong Non degradable 
37 Quercetin Non carcinogen Non mutagen None Strong Non degradable 
38 Resveratrol Non carcinogen Non mutagen None Strong Non degradable 
39 Rosmarinic acid Non carcinogen Non mutagen None Strong Non degradable 
40 Salicyclic acid Non carcinogen Non mutagen None None Degradable 
41 Tangeritin Non carcinogen Non mutagen None Strong Degradable 
42 Theaflavin Non carcinogen Non mutagen None Strong Non degradable 
43 Vitamin C Non carcinogen Non mutagen None None Degradable 
44 Vitamin E Carcinogen Non mutagen Severe None Non degradable 
45 Zeaxanthin Non carcinogen Non mutagen Severe Weak Degradable 
             compound interacted with    targets (    ,            and                    intercalated with    targets (    , 
    ,      and     ),           intercalated with    targets (                 and     ),            intercalated with    targets 
(          and     ) and            intercalated with    targets (    ,      and     ). Even though compounds Astaxanthin and 
Theaflavin showed very good binding affinity, we did not consider them for further docking analysis because they did not comply with the 
Lipinski’s rule. Astaxanthin has greater molecular mass (596.39 Daltons) and greater log P (9.696) value, whereas Theaflavin has greater 
molecular mass (564.13 g/mol) and more than five H-bond donor. The range of the binding affinities of all the compounds lies 
between                 to               .  In addition, the residues surrounding the ligands (within 4 Å) in all docking results provide 
short range polar interactions that stabilize the formation of complex (with the help of delocalization of charges on ligands). It is not possible to 
show all the binding poses but we have shown 07 poses which have maximum binding affinity amoung all of them (Fig. 5). The inhibitor 
constant (Ki) is an indicator of the effectiveness of an inhibitor, with a greatly potent inhibitor being indicated by a low Ki because smaller the Ki, 
the greater the binding affinity and the smaller amount of medication needed in order to inhibit the activity of that enzyme [34]. All of our 
compounds were found to have a very small    value except compound Cinnamic acid, (with 1EQG, 1PBQ, 1QWC, 2FV5, 3G9N, 4B0P and 
4EY5),                   (          ),             (with 1MX1, 1PBQ and 1QWC), Gallic acid (with 3QMO), Iodide (with all 
targets), Lycopene (with 1QWC), Salicyclic acid (with 1QWC, 1UDT, 3G9N, 3QMO and 4DJU), Vitamin C (with 1EQG, 1MX1, 1PBQ, 1Q5K, 
1UDT, 3G9N and 4EY5), Vitamin E (with 1Q5K, 1QWC, 1UDT, 2FV5, 3BKL, 3G9N, 3QMO, 4DJU and 4EY5) and all three drugs commonly 
prescribed in Alzheimer disease (Donepezil, Galantamine and Rivastigmine) that have very poor     values with 4DJU  (Table 6). In this way, 
all of these results suggest that our natural  compounds potentially interfere with Alzheimer associated targets, which should prompt further 
investigations to expose the mechanism of our compounds against Alzheimer disease in vivo. 
Figure 5 Molecular docking poses of the top seven representative compounds: Crystallographic structure of (A)          complexed to 
Butyrylcholinesterase(BuChE)(Pdb id: 4BOP), (B)         acid complexed to Butyrylcholinesterase (BuChE) (Pdb id: 4BOP), (C) 
            complexed to TNF-α converting enzyme (TACE)(Pdb id: 2FV5), (D)           complexed to β-Site amyloid precursor protein 
(Pdb id: 4DJU), (E)          complexed to TNF-α converting enzyme (Pdb id: 2FV5), (F)             complexed to Acetylcholinesterase 
(AChE) (Pdb id: 4EY5), (G)           complexed to Cyclooxygenase-1 (COX-1) (Pdb id: 1EQG). 
 
Table 6:  Calculated         value  from docking energy of 45 natural  compounds against 13 Alzheimer disease associated targets. Compounds that have very poor 
   values are highlighted in grey colour. 
 
              
Compound Names 1EQG 1MX1 1PBQ 1Q5K 1QWC 1UDT 2FV5 3BKL 3G9N 3QMO 4B0P 4DJU 4EY5 
Alpha carotene 4.46E-06 4.46E-06 5.28E-06 4.97E-07 4.46E-06 3.18E-06 1.04E-05 2.69E-06 3.18E-06 3.76E-06 1.37E-06 3.54E-07 6.25E-06 
Apigenin 2.14E-07 1.52E-07 6.96E-07 4.20E-07 1.52E-07 1.29E-07 1.37E-06 8.24E-07 1.92E-06 3.76E-06 1.62E-06 6.96E-07 2.99E-07 
Astaxanthin 9.76E-07 1.62E-06 3.76E-06 4.20E-07 2.85E-05 7.39E-06 1.37E-06 4.68E-08 1.16E-06 3.76E-06 4.20E-07 1.29E-07 1.80E-07 
Beta carotene 1.62E-06 6.25E-06 4.20E-07 3.76E-06 2.53E-07 2.27E-06 2.69E-06 1.92E-06 4.46E-06 1.62E-06 5.88E-07 1.52E-07 6.25E-06 
Canthaxanthin 6.96E-07 1.62E-06 1.92E-06 1.16E-06 1.80E-07 5.28E-06 9.76E-07 2.69E-06 4.20E-07 3.18E-06 1.62E-06 3.76E-06 8.75E-06 
Catechin 4.20E-07 1.29E-07 5.88E-07 7.76E-08 5.54E-08 2.27E-06 3.95E-08 2.38E-08 2.53E-07 2.69E-06 1.70E-08 1.09E-07 9.19E-08 
Chicoric acid 1.37E-06 1.45E-05 4.46E-06 5.88E-07 4.97E-07 6.25E-06 5.88E-07 4.97E-07 3.76E-06 5.28E-06 9.19E-08 4.46E-06 9.76E-07 
Chlorogenic acid 2.69E-06 3.76E-06 8.75E-06 5.88E-07 0.000303 1.72E-05 6.55E-08 1.92E-06 3.18E-06 3.18E-06 8.24E-07 3.76E-06 2.69E-06 
Cinnamic acid 0.00021625 9.30E-05 0.000834 2.85E-05 0.000359 1.72E-05 0.000359 3.38E-05 0.000359 2.41E-05 0.00011 6.64E-05 0.000303 
Coenzyme Q10 3.38E-05 0.000303 0.000303 3.18E-06 0.000183 1.23E-05 1.62E-06 1.04E-05 1.04E-05 7.85E-05 9.76E-07 6.25E-06 9.30E-05 
Cyanidin 1.29E-07 5.28E-06 5.88E-07 6.96E-07 1.62E-06 2.27E-06 9.19E-08 2.99E-07 1.62E-06 2.69E-06 1.80E-07 9.76E-07 3.54E-07 
Daidzein 5.88E-07 4.46E-06 1.92E-06 6.96E-07 7.39E-06 4.97E-07 1.52E-07 9.76E-07 2.27E-06 8.24E-07 8.24E-07 4.20E-07 9.76E-07 
Delphinidin 1.16E-06 1.62E-06 2.69E-06 2.53E-07 4.97E-07 5.28E-06 9.19E-08 8.24E-07 6.96E-07 1.80E-07 1.52E-07 8.24E-07 4.97E-07 
Ellagic acid 4.46E-06 3.18E-06 9.76E-07 1.29E-07 6.96E-07 7.76E-08 8.24E-07 8.24E-07 2.69E-06 1.16E-06 2.01E-08 1.16E-06 7.76E-08 
Epicatechin 2.53E-07 3.76E-06 1.62E-06 4.20E-07 7.76E-08 1.09E-07 1.09E-07 8.24E-07 3.18E-06 2.99E-07 2.99E-07 9.76E-07 9.76E-07 
Epigallocatechin 1.62E-06 3.18E-06 3.18E-06 1.16E-06 8.75E-06 9.19E-08 8.24E-07 8.24E-07 3.18E-06 2.53E-07 3.54E-07 2.27E-06 1.62E-06 
Eriodictyol 1.09E-07 2.69E-06 1.92E-06 4.20E-07 7.39E-06 1.09E-07 6.55E-08 6.96E-07 2.69E-06 1.29E-07 1.29E-07 9.76E-07 8.24E-07 
Gallic acid 2.85E-05 7.85E-05 5.60E-05 4.00E-05 2.85E-05 3.38E-05 8.75E-06 2.41E-05 5.60E-05 0.000154 2.04E-05 9.30E-05 2.04E-05 
Gallocatechin 1.62E-06 3.18E-06 3.76E-06 9.76E-07 8.75E-06 9.19E-08 3.76E-06 9.76E-07 3.76E-06 2.69E-06 1.80E-07 1.92E-06 6.96E-07 
Genistein 2.27E-06 3.76E-06 4.20E-07 3.54E-07 9.19E-08 5.28E-06 2.53E-07 8.24E-07 1.37E-06 1.92E-06 1.62E-06 2.14E-07 4.97E-07 
Glycitein 3.76E-06 1.16E-06 3.18E-06 2.14E-07 1.04E-05 1.92E-06 1.62E-06 1.29E-07 5.28E-06 4.46E-06 1.16E-06 3.34E-08 2.14E-07 
Hesperetin 9.76E-07 2.69E-06 8.24E-07 6.96E-07 6.25E-06 5.28E-06 1.80E-07 6.96E-07 1.62E-06 1.80E-07 2.14E-07 6.96E-07 6.96E-07 
Iodide 0.00116939 0.001384 0.000425 0.000705 0.000359 0.002719 0.000183 0.000595 0.000705 0.001639 0.000503 0.000988 0.002719 
Isorhamnetin 1.09E-07 7.39E-06 2.69E-06 3.54E-07 4.46E-06 5.88E-07 2.99E-07 1.92E-06 1.37E-06 2.53E-07 1.80E-07 6.96E-07 4.46E-06 
Kaempferol 2.27E-06 5.28E-06 3.76E-06 3.54E-07 1.04E-05 4.20E-07 2.53E-07 9.76E-07 9.76E-07 2.99E-07 1.92E-06 5.88E-07 2.99E-07 
Lutein 4.97E-07 6.96E-07 1.72E-05 3.18E-06 1.92E-06 2.27E-06 1.52E-07 2.69E-06 1.37E-06 6.25E-06 4.97E-07 2.99E-07 4.46E-06 
Luteolin 1.37E-06 2.69E-06 4.97E-07 4.20E-07 2.53E-07 6.55E-08 7.76E-08 5.88E-07 1.92E-06 1.80E-07 7.76E-08 6.96E-07 4.97E-07 
Lycopene 2.04E-05 1.45E-05 1.45E-05 2.85E-05 0.040484 3.76E-06 1.37E-06 1.92E-06 1.04E-05 2.85E-05 1.04E-05 6.25E-06 2.85E-05 
Malvidin 5.88E-07 1.04E-05 4.46E-06 5.88E-07 9.76E-07 3.18E-06 4.20E-07 1.37E-06 3.18E-06 3.54E-07 2.99E-07 1.16E-06 1.62E-06 
Melatonin 3.18E-06 1.72E-05 8.75E-06 6.25E-06 9.30E-05 1.62E-06 3.38E-05 5.28E-06 2.04E-05 1.04E-05 1.62E-06 7.39E-06 5.28E-06 
  
Discussion 
Natural products have been used since ancient times and are well recognized as sources of drugs in several human ailments. The healing ability 
of these herbs and medicinal plants draw attention to study natural products as a potentially valuable resource of drug molecules, they are 
evolutionarily optimized as drug-like molecules and remain the best sources of drugs and drug leads [39][40]. In our study, we chose 45 natural 
compounds that have remarkable antioxidant property and act mainly by scavenging free radical species. In recent years, significant  data  have  
been gathered,  indicating  the  level  of  oxidative stress  increase  in  the  brain  in AD condition. This may have a role in the pathogenesis of 
neuron degeneration and death [41]. Thus, protection and inhibition against oxidative stress may be considered an important critarion in the 
Myricetin 1.80E-07 6.25E-06 2.69E-06 2.99E-07 6.25E-06 1.72E-05 1.37E-06 8.24E-07 1.37E-06 1.37E-06 1.29E-07 1.62E-06 5.88E-07 
Naringenin 5.88E-07 4.46E-06 3.18E-06 4.97E-07 1.09E-07 1.09E-07 2.53E-07 8.24E-07 2.69E-06 2.53E-07 2.14E-07 9.76E-07 5.88E-07 
Pelargonidin 8.24E-07 1.16E-06 2.14E-07 7.76E-08 3.95E-08 8.75E-06 1.37E-06 1.29E-07 2.53E-07 1.62E-06 3.95E-08 2.53E-07 2.82E-08 
Peonidin 6.25E-06 4.46E-06 2.69E-06 6.96E-07 1.80E-07 2.53E-07 1.29E-07 1.16E-06 2.69E-06 1.80E-07 2.53E-07 1.16E-06 2.99E-07 
Petunidin 1.37E-06 6.25E-06 2.69E-06 2.53E-07 4.97E-07 1.29E-07 3.54E-07 9.76E-07 6.96E-07 2.69E-06 1.52E-07 9.76E-07 1.37E-06 
Pterostilbene 5.28E-06 2.04E-05 7.39E-06 3.18E-06 1.72E-05 6.96E-07 1.92E-06 3.18E-06 2.85E-05 2.27E-06 7.39E-06 2.69E-06 3.18E-06 
Quercetin 1.09E-07 6.25E-06 2.69E-06 5.88E-07 4.46E-06 1.09E-07 1.80E-07 5.88E-07 4.20E-07 6.96E-07 1.29E-07 9.76E-07 5.88E-07 
Resveratrol 1.72E-05 1.72E-05 8.75E-06 4.46E-06 5.88E-07 2.04E-05 4.97E-07 5.28E-06 2.04E-05 1.72E-05 2.69E-06 3.76E-06 1.37E-06 
Rosmarinic acid 1.62E-06 3.76E-06 5.60E-05 5.88E-07 1.92E-06 6.25E-06 8.24E-07 5.88E-07 4.73E-05 1.16E-06 1.80E-07 3.76E-06 9.76E-07 
Salicyclic acid 9.30E-05 5.60E-05 6.64E-05 4.73E-05 0.000256 0.00011 2.85E-05 2.85E-05 0.000154 0.00011 6.64E-05 0.000183 2.41E-05 
Tangeritin 1.04E-05 1.04E-05 1.92E-06 1.37E-06 1.04E-05 2.53E-07 9.76E-07 1.92E-06 2.69E-06 3.76E-06 6.25E-06 9.76E-07 1.37E-06 
Theaflavin 6.55E-08 4.97E-07 1.21E-08 4.40E-09 2.99E-07 1.37E-06 6.17E-09 5.21E-09 2.99E-07 1.52E-07 3.34E-08 1.21E-08 7.30E-09 
Vitamin C 0.00018266 0.000183 0.00013 0.00011 5.60E-05 0.000303 1.23E-05 3.38E-05 0.000183 7.85E-05 5.60E-05 9.30E-05 0.00013 
Vitamin E 1.04E-05 6.64E-05 4.46E-06 0.00011 0.000359 0.000154 0.000988 0.000216 0.000216 0.000154 4.73E-05 0.00194 0.000216 
Zeaxanthin 1.92E-06 1.92E-06 3.18E-06 1.37E-06 9.76E-07 8.75E-06 1.92E-06 4.20E-07 8.24E-07 5.28E-06 6.96E-07 9.19E-08 1.62E-06 
Drugs commonly prescribed in Alzheimer disease 
Donepezil 3.18E-06 4.46E-06 5.28E-06 4.97E-07 4.46E-06 3.18E-06 1.04E-05 2.69E-06 3.18E-06 3.76E-06 1.37E-06 1.000001 6.25E-06 
Galantamine 1.29E-07 1.52E-07 6.96E-07 4.20E-07 1.52E-07 1.29E-07 1.37E-06 8.24E-07 1.92E-06 3.76E-06 1.62E-06 1.000001 2.99E-07 
Rivastigmine 7.39E-06 1.62E-06 3.76E-06 4.20E-07 2.85E-05 7.39E-06 1.37E-06 4.68E-08 1.16E-06 3.76E-06 4.20E-07 1.000000 1.80E-07 
development of anti-Alzheimer agents. Therefore, treatment with these antioxidant agents might prevent or reduce the progression of AD. These 
natural compounds may prove to be novel anti-Alzheimer agents. In order to exploit all the properties for a compound to behave as a drug, the 
study was done in silico by using different computational tools based on Chemo-informatics or Bioinformatics. The drug-like property 
predictions showed that most of the compounds followed the Lipinski’s rule of five and ADMET. Finally, it can be seen from our docking 
studies also that the compounds exhibit a strong interaction with Alzheimer associated targets. As this is an insilico study, therefore one should 
not forget to consider the complex biological metabolic processes during the onset of Alzheimer. The interaction parameter may vary due to 
multiple interactions in complex system which is another subject of consideration. These results suggest that these compounds may be 
considered to be a kind of novel anti-Alzheimer’s Disease drug agents, which are multi target-directed ligands with not only antioxidant activity 
but also inhibitory and neuroprotective activities. Molecular docking and pharmacokinetics  studies showed that most of our compounds fulfil 
the requirements for an anti-Alzheimer drug, such as ADMET, RO5, non toxicity, binding affinity, inhibition constants, antioxidant, and 
neuroprotective inhibitory properties and good interaction with Alzheimer associate targets. In this way these results suggest that natural 
compounds potentially interfere with Alzheimer associated targets, which should prompt further investigations to expose the mechanism of our 
compounds against Alzheimer disease in vivo. Therefore, we recommend them for future in vivo studies and possible clinical trials. 
Conclusion 
Several natural products are used alone or in combination with other neuroprotective compounds to improve memory and cognition in AD 
patients as supported by various experimental studies.  Altogether, this pioneering study was used to preliminarily investigate the potential 
compounds (drug candidates) from natural products and conventional docking study to analyze the best docked ligands permitted us to know the 
binding mode of compounds. Binding energies of the drug–targets interactions are important to describe how fit the drug binds to the target 
macromolecule (13 Alzheimer disease associated targets).  Further studies are essential to explore the target specific effect of these natural 
compounds on various signalling pathways, mode of action in various brain regions, the ability to cross the blood brain barrier and the 
mechanism behind the synergistic action of the antioxidant agents on the target. Using novel Pharmaceutical engineering and medicinal 
chemistry approach to prepare novel formulations or design new compounds based on natural templates, opens up a new window into using 
natural therapeutic agents against AD.  
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